Navigation Links
Amgen Announces 2012 Third Quarter Dividend
Date:7/19/2012

both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We, or others, could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain;
'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
11. Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... July 29, 2015 , ... Available in select spas and ... a nighttime-specific product that targets fat cells for extreme contouring action. During sleep ... fat cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down ...
(Date:7/29/2015)... , ... July 29, 2015 , ... Nearly everyone has ... diseases. Yet few people realize that a rich source of these cells is teeth—baby ... and teeth that need to be pulled to make room for braces. These ...
(Date:7/28/2015)... July 28, 2015  PDL BioPharma, Inc. (PDL, or ... the Company will release its second quarter 2015 financial ... Wednesday, August 5, 2015, after market close. PDL,s management ... at 4:30 p.m. Eastern Time to discuss the financial ... be available via the webcast link on the PDL ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
Breaking Biology Technology:Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2
... Geneva, Wis. Primex Wireless Inc. ... Visiplex Technologies Inc. in Deerfield. The ... schools, hospitals or other institutions based on the ... held, and terms of the settlement were not ...
... business executives gathered in Milwaukee to hear how ... businesses more competitive, but while several applications are ... outlined during a session of the Wisconsin Innovates ... University of Wisconsin-Madison's RFID Lab , and ...
... The United States ranks a dismal 16th ... national broadband strategy, a member of the Federal Communications ... Midwestern Telecommunications and Technology Conference at Marquette University, Milwaukee ... broadband objectives, but has not coupled that with a ...
Cached Biology Technology:Executives hear about promise, limits of RFID and nanotech 2Executives hear about promise, limits of RFID and nanotech 3Executives hear about promise, limits of RFID and nanotech 4Broadband access needs a champion, FCC commissioner says 2Broadband access needs a champion, FCC commissioner says 3
(Date:7/9/2015)... , July 9, 2015  Unchained Labs just ... its acquisition of Avid Nano. Avid Nano designs, ... (DLS) systems.    Also today, Unchained ... and easiest to use protein sizing system. The ... a protein,s hydrodynamic size, size distribution, aggregation population ...
(Date:7/8/2015)... -- Summary Pancreatic cancer is the 12th most ... a mortality rate of 10.9 deaths per 100,000 people ... has highlighted a significant need for new and improved ... the current market. A highly active pancreatic cancer ... types and mechanisms of action, which provides a striking ...
(Date:7/8/2015)... SAN DIEGO , July 8, 2015 /PRNewswire/ ... of cell-free molecular diagnostics, today announced the launch ... of the Company,s Precision Cancer Monitoring℠ (PCM) technology ... patients receiving one or a combination of the ... and Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient ...
Breaking Biology News(10 mins):Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4
... ingredient in vinegar, acetic acid, can effectively kill ... an international team of researchers from Venezuela, France, ... the online open-access journal of the American Society ... as an inexpensive and non-toxic disinfectant against drug-resistant ...
... have found that a single genetic mutation causes resistance to ... With the continuing rise of resistance the research, published in ... say that this knowledge could help improve malaria control strategies. ... wide range of methods to narrow down how the resistance ...
... Scarborough shows that animal dispersal is influenced by a gene ... The study, which was carried out by UTSC Professor Mark ... first aimed at gaining a functional understanding of how genes ... common fruit flies ( Drosophila melanogaster ), the researchers observed ...
Cached Biology News:Vinegar kills tuberculosis and other mycobacteria 2Vinegar kills tuberculosis and other mycobacteria 3Researchers at LSTM crack the genetic secret of mosquito resistance to DDT and ITNs 2New study shows a genetic link between feeding behavior and animal dispersal 2
...
Full-length cDNA 5-PRIME end of clone CS0DE013YM09 of Placenta of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86TS7] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... 9(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 9(S)-HODE is produced by the lipoxygenation of linoleic ... been detected in atherosclerotic plaques, as an esterified ...
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: